Mitotic Kinase Inhibitors as Therapeutic Interventions for Prostate Cancer: Evidence from In Vitro Studies
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Bentham Science Publishers
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Prostate cancer is one of the devastating diseases characterized by genetic changes leading to uncontrolled growth and metastasis of the cells of the prostate gland and affects men worldwide. Conventional hormonal and chemotherapeutic agents are effective in mitigating the disease if diagnosed at an early stage. All dividing eukaryotic cells require mitotic progression for the maintenance of genomic integrity in progeny populations. The protein kinases, upon activation and de-activation in an ordered fashion, lead to spatial and temporal regulation of the cell division process. The entry into mitosis along with the progression into sub-phases of mitosis is ensured due to the activity of mitotic kinases. These kinases include Polo-Like-Kinase 1 (PLK1), Aurora kinases, and Cyclin-DependentKinase 1 (CDK1), among others. The mitotic kinases, among others, are usually overexpressed in many cancers and can be targeted using small molecule inhibitors to reduce the effects of these regulators on mechanisms, such as regulation of genomic integrity and mitotic fidelity. In this review, we attempted to discuss the appropriate functions of mitotic kinases revealed through cell culture studies and the impact of their respective inhibitors derived in pre-clinical studies. The review is designed to elucidate the growing field of small molecule inhibitors and their functional screening or mode of action at the cellular and molecular level in the context of Prostate Cancer. Therefore, studies performed specifically on cells of Prostatic-origin are narrated in this review, culminating in a comprehensive view of the specific field of mitotic kinases that can be targeted for therapy of Prostate cancer. © 2023 Bentham Science Publishers.
Açıklama
Anahtar Kelimeler
cancer, cell cycle, cell lines, inhibitors, kinases, mitosis, Prostate, antimitotic agent, aurora A kinase, aurora B kinase, cyclin dependent kinase 1, cyclin dependent kinase 2, polo like kinase 1, volasertib, antineoplastic activity, cell culture, cell cycle, cell cycle arrest, cell cycle progression, cell differentiation, cell division, cell growth, cell migration, cell proliferation, cytotoxicity, DU145 cell line, epigenetics, eukaryotic cell, HEK293-A cell line, human, LNCaP cell line, mitogenesis, mitosis, nonhuman, PC-3 [Human prostate carcinoma] cell line, phase 1 clinical trial (topic), progeny, prostate, prostate cancer, Review, RWPE-1 cell line, tumor growth, upregulation
Kaynak
Endocrine, Metabolic and Immune Disorders - Drug Targets
WoS Q Değeri
Scopus Q Değeri
Q3
Cilt
23
Sayı
14
